96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000092-37-BE
(EUCTR)
17/12/202113/09/2021A study of PRA023 in patients with Crohn's DiseaseA Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PRA023
INN or Proposed INN: Not yet assigned
Other descriptive name: PRA023
Prometheus Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2United States;France;Czechia;Czech Republic;Canada;Poland;Belgium;Ukraine;Australia;Russian Federation;Georgia
2EUCTR2021-000092-37-PL
(EUCTR)
19/11/202117/08/2021A study of PRA023 in patients with Crohn's DiseaseA Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PRA023
INN or Proposed INN: Not yet assigned
Other descriptive name: PRA023
Prometheus Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2France;United States;Czechia;Czech Republic;Canada;Belgium;Poland;Ukraine;Australia;Russian Federation;Georgia
3EUCTR2021-000092-37-CZ
(EUCTR)
03/11/202107/06/2021A study of PRA023 in patients with Crohn's DiseaseA Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PRA023
INN or Proposed INN: Not yet assigned
Other descriptive name: PRA023
Prometheus Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2France;United States;Czechia;Czech Republic;Canada;Belgium;Poland;Australia;Georgia
4NCT05013905
(ClinicalTrials.gov)
July 28, 202113/8/2021A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's DiseaseA Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's DiseaseCrohn DiseaseDrug: PRA023 IV;Device: Companion diagnostic (CDx)Prometheus Biosciences, Inc.NULLActive, not recruiting18 YearsN/AAll50Phase 2United States;Australia;Belgium;Canada;Czechia;France;Georgia;Poland;Ukraine